Hesperidin and Experimentally-Induced Arthritis in Male Rats

Sakr, Hader I.

doi:10.18535/jmscr/v5i10.185

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intracellular antioxidants SOD and CAT play a significant role in protecting cells against the damaging effects of ROS [ 46 ]. FM rats showed significantly elevated muscle levels of MDA, with decreased antioxidant activities of SOD and CAT when compared to normal healthy rats.…”

Section: Discussionmentioning

confidence: 99%

Pioglitazone improves skeletal muscle functions in reserpine-induced fibromyalgia rat model

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Fibromyalgia (FM) is characterized by musculoskeletal pain, fatigue, sleep and memory disturbance. There is no definitive cure yet for FM-related health problems. Peroxisome proliferator-activated receptor's (PPAR's) activation is associated with insulin sensitisation and improved glucose metabolism. PPAR-c was reported to alleviate FM allodynia. Limited data are discussing its effect on motor disorders. Objective: To investigate the potential effect of PPAR-c agonists (pioglitazone, as one member of thiazolidinediones (TZD)) on motor dysfunction in reserpine-induced FM in a rat model. Materials and methods: Thirty-six male Wistar rats were divided into negative control (n ¼ 9) and reserpine-induced FM (n ¼ 27) groups. The latter was subdivided into three equal subgroups (n ¼ 9), positive control (untreated FM model), pioglitazone-treated and GW9662-treated. We evaluated muscle functions and activity of chloramphenicol acetyltransferase, superoxide dismutase, malondialdehyde, and serum levels of interleukin-8 and monocyte chemoattractant protein-1. Results: Pioglitazone significantly relieved fatigue, improved muscle performance, reduced inflammatory cytokines and enhanced antioxidant's activity, while GW9662, a known PPAR-c antagonist, aggravated the FM manifestations in the rat model. Conclusion: PPAR-c agonists show a promising role against FM-associated motor dysfunctions.

show abstract

Section: Discussionmentioning

confidence: 99%